Cancer Family
Malignant Head and Neck Neoplasm
CI-CAN-00000236Explore in graph →
1,431 active trials17 approved drugs142 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000236Explore in graph →
Clinical trials
5,448 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (629)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04100694 | Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor | approved for marketing | — | — | Merus B.V.INDUSTRY | 0 | May 20, 2025 | clinicaltrials |
| NCT03906331 | Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 13 | Jan 17, 2025 |
| clinicaltrials |
| NCT04204928 | Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC | approved for marketing | — | — | Blueprint Medicines CorporationINDUSTRY | 0 | Aug 13, 2021 | clinicaltrials |
| NCT00684385 | An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck | approved for marketing | — | — | AstraZenecaINDUSTRY | 4 | Mar 14, 2019 | clinicaltrials |
| NCT03533361 | Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil | approved for marketing | — | — | Eisai Inc.INDUSTRY | 1 | Dec 17, 2018 | clinicaltrials |
| NCT01683110 | Expanded Access of Cabozantinib in Medullary Thyroid Cancer | approved for marketing | — | — | ExelixisINDUSTRY | 1 | Jan 16, 2013 | clinicaltrials |
Data updated 22 days agoSource updated May 20, 2025source: clinicaltrials